Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Armata Pharmaceuticals, Inc. Director's Dealing 2005

Jul 29, 2005

34152_dirs_2005-07-29_9231a505-a790-4b6b-8eb2-ce3473606842.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: TARGETED GENETICS CORP /WA/ (TGEN)
CIK: 0000921114
Period of Report: 2005-07-14

Reporting Person: BIOGEN IDEC INC (10% Owner)
Reporting Person: BIOGEN IDEC MA INC (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2005-07-14 Common Stock, $0.01 Par Value S 8000 $0.79 Disposed 12094178 Indirect
2005-07-14 Common Stock, $0.01 Par Value S 500 $0.7902 Disposed 12093678 Indirect
2005-07-14 Common Stock, $0.01 Par Value S 1000 $0.791 Disposed 12092678 Indirect
2005-07-14 Common Stock, $0.01 Par Value S 15268 $0.80 Disposed 12077410 Indirect
2005-07-14 Common Stock, $0.01 Par Value S 232 $0.81 Disposed 12077178 Indirect
2005-07-15 Common Stock, $0.01 Par Value S 33550 $0.80 Disposed 12043628 Indirect
2005-07-15 Common Stock, $0.01 Par Value S 3000 $0.8002 Disposed 12040628 Indirect
2005-07-15 Common Stock, $0.01 Par Value S 1750 $0.8003 Disposed 12038878 Indirect
2005-07-15 Common Stock, $0.01 Par Value S 4000 $0.801 Disposed 12034878 Indirect
2005-07-15 Common Stock, $0.01 Par Value S 1800 $0.81 Disposed 12033078 Indirect
2005-07-15 Common Stock, $0.01 Par Value S 100 $0.82 Disposed 12032978 Indirect
2005-07-18 Common Stock, $0.01 Par Value S 2500 $0.801 Disposed 12030478 Indirect
2005-07-18 Common Stock, $0.01 Par Value S 2932 $0.81 Disposed 12027546 Indirect

Footnotes

F1: This amendment to the Form 4 originally filed on July 18, 2005 (the "Original Form 4") amends and restates the Original Form 4 in its entirety and is being filed to report the dispositions by the reporting person of Targeted Genetics Corporation stock on July 14, 2005 and to correct the amount of Targeted Genetics Corporation common stock beneficially owned by the reporting person. The Original Form 4 inadvertently did not include the dispositions of Target Genetics stock on July 14, 2005 and, by doing so, overreported the reporting person's beneficial ownership of Targeted Genetics Corporation common stock by 25,000 shares.

F2: Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA Inc., fka Biogen, Inc.